Current Report Filing (8-k)
October 25 2022 - 04:06PM
Edgar (US Regulatory)
false000089626400008962642022-10-252022-10-25
UNITED STATES
SECURITIES AND
EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
October 25, 2022
USANA HEALTH SCIENCES, INC.
(Exact name of registrant as specified in its charter)
Utah
(State or other jurisdiction of incorporation)
001-35024
|
|
87-0500306
|
(Commission File No.)
|
|
(IRS Employer
Identification No.)
|
3838 West Parkway
Boulevard
Salt Lake City,
Utah 84120
(Address of principal executive offices, Zip Code)
Registrant's telephone number, including area code:
(801) 954-7100
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following
provisions:
☐ Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
Common Stock, $0.001 par value per share
|
|
USNA
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant is an emerging growth
company as defined
in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 2.02 |
Results of Operations and
Financial Condition.
|
On October 25, 2022, USANA Health Sciences, Inc. (the “Company” or
“USANA”) issued a press release announcing its financial results
for the third quarter ended October 1, 2022. The release also
announced that the Company will post a document titled “Management
Commentary” on the Company’s website and that executives of the
Company will hold a conference call with investors, to be broadcast
over the World Wide Web and by telephone and provided access
information, date and time for the conference call. The
Company noted that the call will consist of brief remarks by the
Company’s management team, before moving directly into questions
and answers. A copy of the press release, and the Management
Commentary, are furnished herewith as Exhibits to this Current
Report on Form 8-K and are incorporated herein by reference.
These documents will be posted on the Company’s corporate website,
www.usana.com.
The information in this Current Report is being furnished and shall
not be deemed “filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that Section. The information in this Current
Report shall not be incorporated by reference into any registration
statement or other document pursuant to the Securities Act of 1933,
as amended. The furnishing of the information in this Current
Report is not intended to, and does not, constitute a
representation that such furnishing is required by Regulation FD or
that the information this Current Report contains is material
investor information that is not otherwise publicly
available.
Item
7.01 |
Regulation FD
Disclosure |
The information disclosed above under Item 2.02, as well as the
exhibits attached under Item 9.01 below are incorporated herein by
reference.
Item 9.01 |
Financial
Statements and Exhibits. |
Exhibit No.
|
|
Description
|
99.1
|
|
Press release issued by USANA Health
Sciences, Inc. dated October 25, 2022 (furnished herewith).
|
99.2
|
|
Management Commentary provided by
USANA Health Sciences, Inc. dated October 25, 2022 (furnished
herewith).
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
USANA HEALTH SCIENCES, INC.
|
|
|
|
|
|
|
|
By:
/s/ G. Douglas
Hekking
|
|
G. Douglas Hekking,
Chief Financial Officer
|
USANA Health Sciences (NYSE:USNA)
Historical Stock Chart
From Mar 2023 to Apr 2023
USANA Health Sciences (NYSE:USNA)
Historical Stock Chart
From Apr 2022 to Apr 2023